Therapeutic Asset Ratings
169 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
VIPIVOTIDE TETRAXETAN
castration-resistant prostate carcinoma
Janssen Research & Development, LLC
P1
CC
(43)
VIPIVOTIDE TETRAXETAN
prostate cancer
Janssen Research & Development, LLC
P1
CC
(43)
Prizloncabtagene Autoleucel
non-Hodgkin lymphoma
Janssen Research & Development, LLC
P1/2
CC
(43)
Immunoglobulin G4, anti-(human CD3 antigen) (recombinant human monoclonal JNJ-75348780 ?4-chain), disulfide with recombinant human monoclonal JNJ-75348780 ? chain, (229?126?),(232?129?)-bis(disulfide) with immunoglobulin, anti-(human sialic acid-binding Ig-like lectin 2) (recombinant human single-domain VHH fragment)
non-Hodgkin lymphoma
Janssen Research & Development, LLC
P1
CC
(42)
Jnj-64619178
non-Hodgkin lymphoma
Janssen Research & Development, LLC
P1
CC
(42)
Jnj-75229414
prostate neoplasm
Janssen Research & Development, LLC
P1
CC
(42)
Jnj-80038114
prostate neoplasm
Janssen Research & Development, LLC
P1
CC
(42)
Immunoglobulin G4, anti-(human CD3 antigen) (recombinant human monoclonal JNJ-75348780 ?4-chain), disulfide with recombinant human monoclonal JNJ-75348780 ? chain, (229?126?),(232?129?)-bis(disulfide) with immunoglobulin, anti-(human sialic acid-binding Ig-like lectin 2) (recombinant human single-domain VHH fragment)
acute myeloid leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Immunoglobulin G4, anti-(human CD3 antigen) (recombinant human monoclonal JNJ-75348780 ?4-chain), disulfide with recombinant human monoclonal JNJ-75348780 ? chain, (229?126?),(232?129?)-bis(disulfide) with immunoglobulin, anti-(human sialic acid-binding Ig-like lectin 2) (recombinant human single-domain VHH fragment)
castration-resistant prostate carcinoma
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-54179060
B-cell chronic lymphocytic leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-54179060
acute myeloid leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-54179060
castration-resistant prostate carcinoma
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-64264681
acute myeloid leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-64264681
castration-resistant prostate carcinoma
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-64619178
B-cell chronic lymphocytic leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-64619178
acute myeloid leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-64619178
castration-resistant prostate carcinoma
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-70218902
B-cell chronic lymphocytic leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-70218902
acute myeloid leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-70218902
castration-resistant prostate carcinoma
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-74856665
B-cell chronic lymphocytic leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-74856665
castration-resistant prostate carcinoma
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-80948543
B-cell chronic lymphocytic leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-80948543
acute myeloid leukemia
Janssen Research & Development, LLC
P1
CC
(41)
Jnj-80948543
castration-resistant prostate carcinoma
Janssen Research & Development, LLC
P1
CC
(41)
Showing 76 to 100 of 169 assets
Previous
Page 4 of 7
Next
